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ABSTRACT 
 
OBJECTIVE:  The objective of this systematic review is to determine is Kava (piper 
methysticum) safe and effective for reducing anxiety in adult patients 18-65? 
 
STUDY DESIGN: Review of three English language primary randomized controlled studies 
published from 2005-2009.  
 
DATA SOURCES: Randomized, double blind, placebo-controlled trials comparing Kava and 
placebo were found using OVID, PubMed, and CINAHL and COCHRANE databases. 
 
OUTCOMES MEASURED: Each of the three trials assessed the adverse event of hepatotoxicity 
and clinical improvement in anxiety symptoms. Studies utilized to measure change in anxiety 
symptoms included State Trait Anxiety Inventory (STAI-state), Hamilton Anxiety Scale 
(HAMA), the Hospital Anxiety and Depression Scale (HADS), Sheehan Disability Inventory 
(SDI), and Beck Depression Inventory-II (BDI-II).   
 
RESULTS: Three double-blind randomized controlled trials were included in this review.  
Results from the Conner et al study indicate that Kava use is effective in reducing anxiety in 
individuals with low baseline anxiety, but there were no differences between Kava and placebo 
when HAMA scores were > 16 or > 18.  The second study by Sarris et al concluded that the 
response rate after treatment with Kava was 62% with a remission rate of 35%.  The third study 
by Jacobs et al showed a reduction in anxiety symtpoms, but not greater than that of placebo; 
however, the data was not statistically significant.  All three trials demonstrated that kava use 
does not contribute to hepatotoxicity.   
 
CONCLUSIONS: All of the RCTs demonstrate that Kava use is safe and effective at reducing 
anxiety.  However, it seems to be a less efficient option in the overall anxiety score reduction 
when compared to the current available treatment.  In addition, the studies failed to demonstrate 
that Kava has an effect on hepatotoxicity.  
 
KEY WORDS: Kava (piper methysticum), anxiety   
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INTRODUCTION 
Anxiety is becoming an increasing health concern among the general population.  It 
encompasses an extensive range of conditions including: post-traumatic stress disorder, 
obsessive compulsive disorder, panic disorder, phobias, and generalized anxiety disorder (GAD).  
It is the most common mental disorder that affects more than 18% of the U.S. population 18 
years and older (40 million); GAD accounts for 6.8 million, or 3.1%.1  By disrupting the central 
nervous system, specifically sympathetic response, anxiety leads to both psychological and 
physiological manifestations.2 This paper evaluates three double blind, placebo-controlled, 
randomized controlled trials (RCTs), comparing the safety and efficacy of Kava for reducing 
generalized anxiety in adults.   
Anxiety is relevant to the Physician Assistant profession due to its high rates of 
prevalence today.  Half of all PAs work in a primary care setting, where GAD is very common, 
accounting for 3-8% of yearly office visits, (>6.8 million).3,4   It accounts for almost one third of 
the total health expenses for mental illness, with an estimated $42 billion spent yearly.  
Additionally, anxiety sufferers are three to five times more likely to seek medical care and six 
times more likely to be hospitalized than those without anxiety.1  Recent data shows that a 
quarter of the population will at some point experience anxiety that severely impacts their daily 
activities, including sleep, appetite, and thinking and are in need of prompt health professional 
advice.5      
Although the exact cause of GAD is unknown, it is believed to be as a result of under-
activation of serotoninergic and over-stimulation of noradrenergic neurotransmitters, as well as 
disturbance of the gamma-aminobutyric acid (GABA) system.2  It is characterized by frequent, 
relentless worry and anxiety that is out of proportion to the situation for at least six months. 2,3 
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Patients also often experience restlessness, fatigue, difficulty concentrating, irritability and 
muscle disturbances.  The diagnosis of GAD is made based on history and DSM IV criteria.  It 
can be rated by the Hamilton Anxiety Scale (HAMA) based on symptom severity, such as: 
behavior, anxious/depressed mood, fears, intellectual impairment, tension, insomnia 
cardiovascular, respiratory, GI, GU, autonomic, or somatic symptoms.6   
Usual methods used to treat anxiety disorder include a combination of psychotherapy and 
pharmacotherapy.  Cognitive Behavioral Therapy (CBT) has been proven to be most effective of 
the psychotherapies available, and when used in conjunction with medicine demonstrates to be 
twice as effective in establishing remission.  Among the pharmacotherapy options, 
benzodiazepines are best in management of short-term symptoms and for those with severe 
impairment of function, in need of a quick-acting anxiolytic.  However, due to their addiction 
and withdrawal potential, selective serotonin reuptake inhibitors (SSRIs) are the best-tolerated 
medications for long-term use.  Given that SSRIs take 4-6 weeks to show symptom 
improvement, currently, the initial best treatment option includes a combination of 
benzodiazepines and SSRIs. 2 
The above regimens are effective treatment options for patients with anxiety, although 
most target multiple conditions and favorable effects and adverse reaction vary among each 
patient.  Additionally, they may need to be used long-term in order to prevent relapse, which 
occurs in 25% of all patients within the first month of discontinuation, and in 60-80% over a 
year.  Kava may be a natural anxiolytic alternative to these regimens in the reduction of anxiety 
and will be discussed further in this review.2  
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OBJECTIVE 
The objective of this selective EBM review is to determine, “Is Kava (piper methysticum) 
safe and effective for reducing anxiety in adult patients 18-65?”   
METHODS 
The three studies utilized in this review were randomized controlled clinical trials and 
met the following criteria:  The population consisted of adults ages 18-65 who met DSM-IV 
anxiety criteria.  The intervention used was Kava 300mg, 280mg and 1,250mg.  The treatment 
group receiving Kava was compared to the group receiving a virtually matched placebo.  
Outcomes measured included safety of Kava concerning drowsiness and hepatotoxicity and its’ 
efficacy regarding anxiety.   
Key words used to locate the literature consisted of Kava (piper methysticum) and 
anxiety.  All articles were published in English and published in peer-reviewed journals.  The 
articles were researched by the author and obtained via OVID, PubMed, CINAHL, and 
COCHRANE databases.  Articles were selected based on relevance and significance of outcomes 
to the patients (POEMS).  Inclusion criteria consisted of double blind, RCT studies, included 
patient oriented outcomes, and were published after 1996.  Exclusion criteria included: patients 
under 18 years old, recent anxiety/depression treatment or disorder, substance abuse, 
breastfeeding, pregnancy, history of liver disease, lifetime history of bipolar disorder, psychiatric 
disorder, organic brain syndrome, or mental retardation.  Statistics that were reported and utilized 
are relative risk (RR), relative risk reduction (RRR), absolute risk increase (ARI), absolute risk 
reduction (ARR), number needed to harm (NNH), number needed to treat (NNT), p-value, and 
χ²-distribution.7,8,9 
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Demographics and characteristics of the studies utilized for this review are displayed in Table 1.   
Table 1. Demographics and characteristics of included studies  
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Jacobs4, 
2005 
RCT 391 >21 
(mean:
41.4) 
Adults who 
scored > 40 
points on STAI; 
> 21 who reside 
in US and have 
access to email 
and WWW with 
anxiety 
documented by 
STAI 2 separate 
times 
Pts who use 
sedative-
hypnotic or 
benzos; drink >2 
alcoholic drinks 
daily; hx of liver 
ds; pregnancy; 
breastfeeding 
72 1) 1 100 mg 
Kava softgel 
capsule TID + 
2 placebo 
valerian softgel 
capsules 1 hr 
before bed 
2) 2 3.2 mg 
valerian softgel 
capsule 1 hour 
before bed +  1 
placebo-Kava 
softgel capsule 
TID 
3) Placebo-
Kava + 
placebo-
valerian softgel 
capsules 
Connor5, 
2006 
RCT 64 > 18 
(mean:
52.5; 
49.9; 
43.6) 
Adults with 
DSM-IV GAD 
– HAMA score 
of 16, 12-20, or 
18 with 
symptoms for 6 
mos 
Hx of 
anxiety/mental 
ds; substance 
abuse; abnl 
lab/EKG; 
psychotropic tx, 
pregnancy; 
breastfeeding 
N/A 1 70 mg Kava 
capsule BID x 
1 week; then 1 
140 mg Kava 
BID 
 
Sarris6, 
2009 
RCT 60 18-65 
(mean:
44.4, 
43.1) 
Adults with at 
least 1 mo of 
persistent 
worry/anxiety 
scoring > 10 on 
BAI 
Hx of bipolar 
psychosis; 
suicide ideation; 
substance abuse 
within 6 mo; use 
of 
antidepressant, 
benzos, or 
opiates in past 1 
mo; concurrent 
psychological tx  
19 5 250 mg Kava 
tabs QD x 3 
weeks  
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OUTCOMES MEASURED 
All outcomes measured in the trials were based on patient oriented evidence that mattered 
to the patients and assessed the adverse event of hepatotoxicity and clinical improvement in 
anxiety symptoms.  Jacobs et al measured the change in anxiety symptoms based on the State 
subtest of the State Trait Anxiety Inventory (STAI-State) and reported adverse events throughout 
the study, including hospitalizations, ER visits, or any new symptoms or illnesses by contacting 
the on-call physician by e-mail or telephone.7  The Conner et al study made assessments via the 
Hamilton Anxiety Scale (HAMA):  scored 0 to 4, the Hospital Anxiety and Depression Scale 
(HADS), and the Sheehan Disability Inventory (SDI).8  The Sarris et al study participants were 
assessed on the HAMA Scale, Beck Depression Inventory-II (BDI-II): 21 questions scored 0 to 
3, and were asked to obtain liver function tests within 3 days.9  
 
RESULTS 
The results of two of the three trials, Jacobs et al and Connor et al, converted continuous 
data into dichotomous in order to assess the symptomatic improvement in anxiety and the safety 
of Kava use.  The Sarris et al study used continuous data that could not be converted to 
dichotomous.  
Connor et al study stratified participants based on the baseline entry criterion scores; it 
demonstrated that daily use of 280 mg Kavalactones titrated for a total of four week duration was 
effective in reducing generalized anxiety in individuals with low baseline anxiety (HAMA entry 
scores 12-20), yet no differences between Kava and placebo were found when HAMA scores 
were > 16 or > 18 with four and eight weeks of treatment, respectively (Table 2).  Furthermore, 
the RRR was calculated to be 25% and the ARR was 5%.  NNT was 20 patients and the p-value 
was determined to be statistically significant at p<0.04 and p<0.05 on the HAMA and HADS 
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assessments (Table 3).  The NNT value indicates that for every 20 patients treated with 280 mg 
of Kava daily, one more patient would have complete remission of anxiety than if treated with 
placebo.  In addition, in this limited sample, Kava use appeared safe with respect to liver 
function, with all values remaining well below the normal reference range (Table 4).   
Table 2. Baseline entry criteria and symptom severity before and after treatment  
Study Treatment 
Duration 
Patients    
(n) 
Entry Criteria  Before  After Anxiety 
Reduction * 
HAMA 
Trial 1 
4 weeks 35 Baseline HAMA > 
16 
Kava: 21 
Placebo: 18 
Kava: 13 
Placebo: 10 
Kava: 8 
Placebo: 8 
HAMA 
Trial 2 
4 weeks 13 Baseline HAMA 
12-20 
Kava: 17 
Placebo: 14 
Kava: 7.5 
Placebo: 10 
Kava: 9.5 
Placebo: 4 
HAMA 
Trial 3 
8 weeks  16 Baseline HAMA > 
18 
Kava: 32 
Placebo: 24 
Kava: 20 
Placebo: 12 
Kava: 12 
Placebo: 12 HAMA: Hamilton Anxiety Scale * Points reduction in HAMA score before and after treatment with Kava and placebo  
Table 3. Analysis of efficacy of Kava use for remission of generalized anxiety.  
Study Relative risk 
reduction (RRR) 
Absolute risk 
reduction (ARR) 
Number needed to 
treat (NNT) 
p-value  
Connor5, 2006 25% 5% 20 patients HAMA: p<0.04 
HADS:  p<0.05 
 
Table 4. 8 
Comparison of liver enzyme scores after treatment with Kava and placebo (mean SD) 
                                     _______________Treatment__________________ 
                                                     Before                             After                                    P 
SGOT 
    Kava 
    Placebo 
 
25.9 (6.8) 
26. 8 (9.5) 
 
30.0 (14.5) 
24.6 (5.0) 
 
NS 
SGPT 
    Kava 
    Placebo 
 
27.9 (13.8) 
28.0 (12.6) 
 
34.3 (24.7) 
26.7 (9.1) 
 
NS 
Alkaline Phosphatase 
    Kava 
    Placebo 
 
67.9 (16.9) 
67.6 (12.0) 
 
69.6 (14.4) 
63.2 (19.8) 
 
NS 
Total bilirubin 
    Kava 
    Placebo 
 
0.55 (0.23) 
0.49 (0.20) 
 
0.50 (0.24) 
0.48 (0.18) 
 
NS 
Reference ranges: serum glutamate-oxaloacetate transaminase (SGOT): 10-60 U/l; serum 
glutamate-pyruvate transaminase (SGPT): 10-60 U/l; alkaline phosphatase: 30-135 U/l; total 
bilirubin: 0.2-1.2 mg/dl  
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Sarris et al study started with 182 volunteers, 141 of who were excluded due to no stable 
anxiety symptoms, use of antidepressants or anti-anxiety medication, bipolar depression, liver 
dysfunction, high alcohol or drug use, and positive placebo response.  The primary result 
outcomes were measured via HAMA with secondary outcomes measured by the BAI scale after 
administration of 250 mg of Kava daily for a total of three weeks.  The HAMA scale showed 
statistically significant (p<0.0001) results where anxiety was reduced by -9.9 points (CI = -12.7, 
-7.1) below pretreatment levels during the first controlled trial and by -10.3 (CI = -14.7, -5.8) 
points during the second trial, compared with a -0.8 (CI = -4.3, +2.7) decrease with placebo use 
during trial one, and an increase of +3.3 (CI = -0.2, +6.8) points in trial two.  The BAI scale also 
revealed statistically significant data (p=0.001) in support of Kava, with reduction by -7.2 (CI = 
-10.8, -3.5) points and -8.1 (CI = -12.5, -3.6) for trial one and two, respectively.  Placebo use in 
trial one showed a -1.6 (CI = -5.6, +2.5) point reduction, and an increase of +1.4 (CI = -2.0, 
+4.9) points in trial two (Table 5).  In addition, serious adverse effects, including hepatotoxicity 
were not evident in either trial based on participant reporting.  Furthermore, the study concluded 
that the response (> 50% reduction below baseline on HAMA) rate after treatment with Kava 
was 62% with a remission rate of 35%. 9 
Table 5. Symptom severity before and after treatment with Kava and placebo.9 
Mean (SD) 
 
Outcome 
measure 
 
Pretreatment score (SD) 
 
Trial 1  
 
Trial 2  
 
p 
HAMA KP   21.16 (3.52) 
PK   20.28 (4.78) 
KP   11.26 (4.47) 
PK   19.50 (7.26) 
KP   14.58 (5.86) 
PK   9.22 (5.96) 
<0.0001 
BAI KP   16.47 (4.90) 
PK   17.94 (5.98) 
KP   9.32 (6.49) 
PK   16.39 (10.16) 
KP   10.74 (6.04) 
PK   8.33 (7.39) 
0.001 
KP: Kava week 1, Placebo week 2; PK: Placebo week 1, Kava week 2  
Jacobs et al converted continuous data into dichotomous for NNH, but no dichotomous 
data was provided for NNT.  To determine effectiveness in anxiety reduction, symptom severity 
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was assessed using the STAI scale.  Participants who received four weeks of Kava therapy had a 
total reduction in anxiety of -11.8, whereas those on placebo had a reduction of -14.4 (Table 6).  
However, this difference between groups is +2.7 with a 95% CI (-0.8, +6.2) and is not 
statistically significant.  All participants were contacted either by e-mail or postal mail 
concerning hepatotoxicity, since this study was conducted before safety warnings were issued; 
none of the participants reported any adverse events.  Additionally, side effects of similar 
frequency occurred between Kava and placebo groups.7  In regards to headache and drowsiness, 
the RRI was calculated to be 21% and ARI -5%. NNH was -20 patients at a confidence interval 
of 95%.  The negative value of NNH shows that for every 20 patients treated with Kava, one 
fewer patient would experience headache or drowsiness when compared to placebo.   
Table 6. Symptom severity before and after treatment with Kava and placebo. 
Mean (SD) 
 
Outcome measure: 
STAI 
 
Kava 
(n=121) 
 
Placebo  
(n=135) 
 
Kava – Placebo 
(95% CI)  
Baseline 56.8 (9.6) 56.6 (9.3)  
Week 2 – change 
from baseline 
-9.2 (9.9) -11.1 (11.4)  
Week 4 – change 
from baseline 
-11.8 (12.3) -14.4 (12.9) +2.7 (-0.8 to +6.2) 
STAI: State-Trait Anxiety Inventory  
Table 7.  
Analysis of safety of Kava use regarding headache and drowsiness for generalized anxiety.  
Study Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
CI 
Jacobs4, 2005 - 21% - 5% -20 patients 95% 
 
DISCUSSION 
Kava is a native plant found in the South Pacific and has many reported uses, including 
those for anxiety, insomnia, skeletal muscle relaxation, and ADD/ADHD in children.  Its use as 
an anxiolytic is becoming more popular, especially in Western Europe for the treatment of 
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anxiety and nervous tension. It works by exerting its effects on the amygdala in the limbic 
system, which is responsible for generation of emotion.8,10  Currently, the FDA is trying to 
ascertain Kava’s effects on hepatotoxicity and the safety of its use.  Presently, it is 
contraindicated in pregnancy and lactation, as well as Parkinson’s disease due to it’s potential 
dopamine antagonistic effects.10 
As a result of hepatotoxicity, Kava use has been banned in the United States.  However, 
Kava use in regards to hepatotoxicity has been proven safe; the toxicity patterns that had seemed 
to emerge may be as a result of difference in genetics and human metabolism.  In addition, the 
preparations used to make kava tablets, such as ethanol and the use of kava stems and leaves as 
opposed to only the root extract is what had lead to hapatotoxicity and the current ban.  
Moreover, studies have shown that Kava inhibits cytochrome isoenzymes 1A2, C29, 2C19, 2D6, 
and 3A4 and concomitant use with other medications could lead to hepatotoxicity.  Newer 
formulations of Kava, which exclude methysticin and dihydromethysticin may lead to 
developments of a safer form of Kava.8  Additionally, Kava side effects were comparable to and 
possibly even superior to most benzodiazepine trials and did not demonstrate any withdrawal 
effects upon discontinuation, as can be seen with benzodiazepines and SSRIs.8,9 
Connor and Sarris et al studies showed a decrease in anxiety scores when compared to 
placebo, while the Jacobs et al study shows Kava reduces symptoms of anxiety but not greater 
than that of placebo.  Although data in this review supports the use of Kava in reduction of 
anxiety, not all of the data presented is clinically significant.  Even though the three studies 
provide adequate data, the small sample size may not be adequately large enough to show a 
difference in treatment such as that of the Conner et al study that only shows effectiveness 
among 13 participants with low base-line anxiety (HAMA score 12-20).  In addition, this 
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reduction may not be clinically significant enough to therapeutically be beneficial to patients 
with generalized anxiety.   
 Certain limitations to the studies exist and many factors may have affected the outcome.  
One of the factors is that participants have strong beliefs in the efficacy of natural alternatives, 
which may have influenced response to treatment, thereby not showing a difference in Kava use 
versus placebo.  Limitations of the studies include: less consistent responses from patients that 
used the internet for responses, resulting in misleading information; small sample sizes; 
differences regarding duration of GAD prior to study entry and duration of treatment; and the 
average patient population (50 years) is higher than the average age of participants with 
GAD.7,8,9 
CONCULSION:  
 Kava has been proven to be safe and effective at reducing anxiety in adults 18-65.  
However, considering the inconsistencies and inconclusiveness of the data, other therapies may 
be more beneficial at this time with pending FDA studies, which are thereby limiting further 
research in the US currently.  Therefore, it can be concluded that Kava therapy alone is a less 
efficient treatment option, but is still successful in reducing anxiety with comparable side effects 
to other available options.  Further studies can refine the population of interest by setting a more 
narrow age-requirement range; for example: 18-25; 26-33; 34-41; 42-50; 51-60.  By targeting a 
smaller population in similar age groups, the population better relates to one another and anxiety 
and stress response at study initiation will not be as varied.  Future studies can also do a pre and 
post liver enzyme study among all participants to get a better understanding of hepatotoxicity.   
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